Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,651 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 10, 2026, 10:51 AM EDT
Completed No phase listed Observational

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)

NCT00246194
View directory record Official record
Conditions
Schizophrenia
Interventions
risperidone (RISPERDAL CONSTA)
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Sodium Oxybate in Schizophrenia With Insomnia

NCT00594256
View directory record Official record
Conditions
Schizophrenia, Insomnia Related to Schizophrenia (307.42)
Interventions
Sodium Oxybate
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone

NCT03527186
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Long Beach, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal® Consta®, LY03004
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Orange County, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

NCT00034801
View directory record Official record
Conditions
Depression, Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, ziprasidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
30
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 10, 2026, 10:51 AM EDT
Terminated Not applicable Interventional

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

NCT00183612
View directory record Official record
Conditions
Bipolar Disorder, Psychotic Disorders
Interventions
Olanzapine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 10, 2026, 10:51 AM EDT
Recruiting Phase 4 Interventional

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

NCT07483294
View directory record Official record
Conditions
Psychosis; Acute
Interventions
risperidone, aripiprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 10, 2026, 10:51 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

FAAH Availability in Psychiatric Disorders: A PET Study

NCT04404712
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder, Psychosis
Interventions
[11C]MK-3168
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

NCT01488929
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms, Cognitive Dysfunction
Interventions
TC-5619, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Garden Grove, California • Glendale, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

NCT00435370
View directory record Official record
Conditions
Smoking Cessation, Schizophrenia
Interventions
Tropisetron, Placebo, Risperidone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 2 Interventional

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

NCT00097942
View directory record Official record
Conditions
Schizophrenia
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
National City, California • San Diego, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Not applicable Interventional

Community-Based Cognitive Training in Early Schizophrenia

NCT01973270
View directory record Official record
Conditions
Schizophrenia, Psychosis
Interventions
Neuroadaptive cognitive training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 35 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07549581
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

NCT01348100
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin MEG Study

NCT02568709
View directory record Official record
Conditions
Schizophrenia, Oxytocin, Magnetoencephalography (MEG), Social Cognition
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 10, 2026, 10:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 70 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 2 Interventional

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164
View directory record Official record
Conditions
Schizophrenia
Interventions
Divalproex Sodium Extended-Release Tablets, Olanzapine, Risperidone
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

NCT01429740
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-05180999, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Video Consent Versus Routine Consent for Participation in Research Studies

NCT00430391
View directory record Official record
Conditions
Schizophrenia
Interventions
DVD Consent, Routine Control
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

NCT00085891
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Birmingham, Alabama • Cerritos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 10, 2026, 10:51 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

NCT05890768
View directory record Official record
Conditions
Psychosis
Interventions
Lumateperone, Risperidone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 10, 2026, 10:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 10, 2026, 10:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCT00307203
View directory record Official record
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 10, 2026, 10:51 AM EDT